The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patie...

Descripción completa

Detalles Bibliográficos
Autores principales: La Rosée, F., Bremer, H. C., Gehrke, I., Kehr, A., Hochhaus, A., Birndt, S., Fellhauer, M., Henkes, M., Kumle, B., Russo, S. G., La Rosée, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282206/
https://www.ncbi.nlm.nih.gov/pubmed/32518419
http://dx.doi.org/10.1038/s41375-020-0891-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282206/
https://www.ncbi.nlm.nih.gov/pubmed/32518419
http://dx.doi.org/10.1038/s41375-020-0891-0

Ejemplares similares